Casma: Tailoring autophagy targets to indications
How Third Rock portfolio company Casma is evaluating the entire autophagy pathway for a broad swath of diseases
Rather than focus on a single target, Casma is evaluating the entire autophagy pathway for a broad swath of diseases.
According to Casma Therapeutics Inc. CEO Keith Dionne, inappropriate accumulation of autophagy substrates is shared by seemingly disparate diseases, including Parkinson's disease, non-alcoholic steatohepatitis (NASH) and lysosomal storage disorder Pompe disease. The commonality of substrate accumulation presents the cellular recycling pathway as a common therapeutic target.
Third Rock Ventures, where Dionne was